Wisevoter
U.S.

IN8bio Reports $4.6 Million Q3 Net Loss

The biotech company posted a wider quarterly loss than a year earlier as research spending rose and it added a new research leader.

Updated on Nov. 5, 2026 in Biotech

Bold flat-color editorial illustration of clear glass vials and a steel pipette rack on a laboratory bench, one vial holding an amber liquid.
IN8bio reported a $4.6 million net loss for the quarter ended September 30, 2026, up from $3.9 million a year earlier, as preclinical spending rose. AI Illustration. Upload story photo >

IN8bio reported a net loss of $4.6 million, or $0.24 per share, for the three months ended September 30, 2026, compared with $3.9 million, or $0.85 per share, a year earlier. The company also said it had cash of $14.0 million as of September 30, 2026.

Why it matters

The larger loss reflects rising spending on the company's T cell engager platform as it advances preclinical work toward human trials. The company's cash position will shape how long it can fund that development.

The third-quarter filing shows R&D spending up to $2.6 million from $2.1 million and cash rising to $14.0 million from $10.7 million a year earlier. The company has not said how long current cash will fund operations beyond the reported period.

The players

IN8bio

IN8bio is a clinical-stage biotechnology company developing gamma delta T cell therapies for cancer, based in New York.

Oxana Polyakova, Ph.D.

Oxana Polyakova is a scientist who joined IN8bio as Senior Vice President of Research & Development, leading its research programs.

The details

The quarterly loss increase was driven mainly by preclinical costs tied to IN8bio's T cell engager platform, along with higher professional services spending that lifted general and administrative expenses. In September 2026 the company named Oxana Polyakova, Ph.D., as Senior Vice President of Research & Development.

Timeline

  1. July 2026: Published Phase 1 INB-200 glioblastoma data in the Journal of Clinical Oncology.

  2. September 2026: Oxana Polyakova joined as Senior Vice President of Research & Development.

  3. October 2026: INB-619 was included in a review in Nature Reviews Drug Discovery.

  4. September 30, 2026: Third quarter ended with reported net loss and cash position.

  5. Year-end 2026: Company expects to report initial in vivo preclinical data for INB-619.

Big Picture

IN8bio's T cell engager platform is the program behind the rising preclinical spending, with INB-619 as its lead candidate moving toward initial in vivo data. The quarter's figures show the company still funding that work from a modest cash base.

For patients and investors following cancer cell therapy, the quarter signals that INB-619 is still preclinical and years from any clinical availability. Shareholders should weigh the wider per-share loss against the company's remaining $14.0 million cash position.

The takeaway

Early-stage biotech losses often rise before clinical milestones, so the quarterly cash balance is the figure to watch for how long a company can keep its programs running. For IN8bio, the next concrete marker is the year-end 2026 preclinical data for INB-619.

What happens next

IN8bio expects to report initial in vivo preclinical data for INB-619 by year-end 2026.

Further reading

Explore more biotech news for context on how cell therapy companies are funding early-stage programs.

Source note: This article includes information reported by The Manila times.